Trust Signals
Every major claim on this page is graded against the best available evidence type. We distinguish rodent data from human RCT data explicitly and concede where approved drugs outperform research peptides. We do not sell the peptides discussed here. No affiliate relationship influences rankings.
Key Takeaways
- BPC-157 has the broadest rodent evidence for hepatoprotection, including reduced ALT and AST in toxic hepatitis models, but zero completed human RCTs for liver endpoints.
- GLP-1 receptor agonists (semaglutide, liraglutide) are the only peptide class with human RCT evidence for reducing liver fat in NAFLD and outperform all research peptides on this endpoint.
- Thymosin beta-4 (TB-500) modulates hepatic stellate cell activity in animal models, relevant to fibrosis, but has no liver-specific human trial data.
- Impure research peptides are a realistic hepatotoxicity risk: endotoxin contamination can drive inflammatory liver injury independently of the peptide itself.
- NAC, a dipeptide precursor, has FDA-approved status for acetaminophen-induced liver failure and more robust human evidence than any research peptide for acute liver protection.
What Is the Best Peptide for Liver Health?
BPC-157 is the most evidence-supported research peptide for liver protection based on rodent studies demonstrating reduced hepatic enzyme elevation and attenuated fibrosis after toxic insult. For NAFLD specifically, GLP-1 peptides (semaglutide) carry the only human RCT evidence. No research peptide has cleared a liver-specific human clinical trial as of mid-2026.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: All Major Claims Graded
- BPC-157: Mechanism With Real Numbers
- Thymosin Beta-4 (TB-500) and the Liver
- GLP-1 Peptides: The Human Evidence Leader
- Other Peptides With Liver-Relevant Data
- What Most Pages Get Wrong About Liver Peptides
- Honest Head-to-Head: Peptides vs. Proven Alternatives
- The Chemistry Behind Storage and Stability Rules
- Operational Guide: Reading a COA and Dosing Tables
- FAQ
- Sources
Evidence Ledger: All Major Claims Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| BPC-157 reduces ALT/AST in toxic hepatitis models | Animal (rodent RCT) | Positive (hepatoprotective) | Moderate (animal only) |
| BPC-157 attenuates hepatic fibrosis | Animal + cell culture | Positive | Low (no human data) |
| TB-500 modulates hepatic stellate cells | Cell culture and animal | Positive (anti-fibrotic) | Low |
| Semaglutide reduces liver fat in NAFLD | Human Phase 2 RCT (Newsome et al., NEJM 2021) | Positive | High |
| Liraglutide improves NASH histology | Human RCT (Armstrong et al., Lancet 2016) | Positive | High |
| NAC prevents acetaminophen-induced liver failure | Human RCT, FDA-approved indication | Positive | High |
| BPC-157 is safe in humans at hepatic doses | No liver-specific human safety trial | Unknown | Very Low |
| Endotoxin in peptide products causes liver inflammation | Mechanism well-established (LPS-TLR4 pathway) | Harm | High (mechanism), Low (peptide-specific incidence) |
BPC-157: Mechanism With Real Numbers
BPC-157 (Body Protection Compound 157) is a 15-amino acid synthetic peptide derived from a partial sequence of human gastric juice protein. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
In rodent models of alcohol- and NSAIDs-induced hepatotoxicity, Sikiric and colleagues at the University of Zagreb documented reductions in serum ALT and AST elevations with BPC-157 administration. The dosing in those studies was approximately 10 micrograms per kilogram bodyweight, given either intraperitoneally or by gavage. The group published multiple iterations of this work across the 2000s and 2010s in journals including the Journal of Physiology-Paris and Life Sciences.
The proposed mechanism centers on the nitric oxide (NO) system: BPC-157 appears to upregulate endothelial nitric oxide synthase (eNOS) activity, supporting hepatic microcirculation and reducing ischemia-reperfusion injury. Secondary to this, downstream angiogenic signaling (including effects on VEGFR2) may support hepatocyte recovery. BPC-157 also interacts with the FAK-paxillin pathway, relevant to cell migration and wound repair.
What this mechanism does NOT prove: NO-pathway upregulation in rodents does not translate automatically to fibrosis reversal or meaningful histological improvement in humans. Rodent liver regenerative capacity differs substantially from human. The Sikiric group's work, while prolific, has limited independent replication by other research groups, which reduces confidence in the effect size.
Thymosin Beta-4 (TB-500) and the Liver
Thymosin beta-4 is a 43-amino acid endogenous peptide involved in actin sequestration and cell motility. In the liver context, the relevant biology involves hepatic stellate cells (HSCs): activated HSCs are the primary drivers of hepatic fibrosis, and thymosin beta-4 has been shown in cell and animal models to reduce HSC activation markers including alpha-smooth muscle actin (alpha-SMA).
Research from groups studying cardiac and hepatic fibrosis (published in journals including Hepatology) has explored thymosin beta-4 fragments, particularly the N-terminal tetrapeptide Ac-SDKP, as anti-fibrotic agents. This fragment is generated from thymosin beta-4 by prolyl oligopeptidase and inhibits transforming growth factor beta-1 (TGF-beta-1) signaling, a central fibrosis pathway.
Important distinction: TB-500, sold as a research peptide, is thymosin beta-4 or a fragment. Thymosin alpha-1 (Zadaxin) is a completely different peptide approved in some countries for hepatitis B and C. These are frequently confused on wellness forums. Evidence for thymosin alpha-1 in liver disease does not apply to TB-500.
GLP-1 Peptides: The Human Evidence Leader
For anyone primarily concerned with liver fat reduction or NASH improvement, GLP-1 receptor agonist peptides have the most robust human evidence and should be the reference comparator for all research peptides.
The Newsome et al. trial (NEJM 2021, n=320) tested semaglutide 0.4 mg daily versus placebo in NASH patients. Liver fat reduction was confirmed by MRI-PDFF. NASH resolution without worsening of fibrosis occurred in significantly more semaglutide patients than placebo, though fibrosis improvement itself did not reach significance. Armstrong et al. (Lancet 2016, n=52) showed liraglutide 1.8 mg daily achieved NASH resolution on histology in 39% of patients versus 9% on placebo.
These are prescription medications with a well-characterized side effect profile. They do not belong in the same category as unregulated research peptides, but they cannot be ignored in an honest comparison.
Other Peptides With Liver-Relevant Data
Selank and Semax: These Russian-developed nootropic peptides have some published hepatoprotective data in rodent alcohol models. The literature is almost entirely from Russian-language journals with limited independent verification. Confidence: Very Low.
AOD-9604: A fragment of human growth hormone (hGH), studied primarily for fat metabolism. Some lipid-lowering effects in rodents could theoretically reduce hepatic steatosis. No liver-specific human data. Confidence: Very Low.
NAC (N-acetylcysteine): Technically a dipeptide precursor and not a conventional peptide, but biochemically relevant. It is the most evidence-supported compound for acute liver protection available without a prescription in most markets. Its mechanism is direct glutathione repletion in hepatocytes, which is the dominant defense against oxidative hepatotoxicity.
What Most Pages Get Wrong About Liver Peptides
1. They conflate animal efficacy with human efficacy. The gap between rodent hepatotoxicity models and human chronic liver disease (NAFLD, NASH, fibrosis) is enormous. Rodents have higher liver regenerative capacity, different gut microbiome composition influencing liver inflammation, and are studied at doses that have no validated human equivalent. Nearly every research peptide article treats Sikiric-group rodent data as proof of human benefit. It is not.
2. They ignore the contamination risk. Research peptide products are not manufactured under pharmaceutical GMP. A 2023 analysis by Cohen et al. in JAMA (examining a broader category of compounded peptide products) found purity and concentration discrepancies in a meaningful proportion of samples tested. Endotoxins (lipopolysaccharide, LPS) are a common contaminant in poorly manufactured peptides. LPS activates TLR4 receptors in liver Kupffer cells, driving NFkB-mediated inflammatory signaling. Injecting an endotoxin-contaminated peptide to "protect" the liver could do the opposite.
3. They do not explain bioavailability of oral BPC-157. BPC-157 is marketed in both injectable and oral capsule forms. The injectable form has documented systemic exposure in rodent studies. Oral BPC-157 proponents cite the gastric origin of the parent protein and local GI effects as justification. However, peptide degradation by gastric proteases (pepsin at low pH, trypsin and chymotrypsin in the small intestine) is substantial for most 15-amino-acid sequences without special modification. Oral bioavailability of BPC-157 reaching the liver systemic circulation has not been measured in humans. The oral form may be relevant for direct GI mucosal effects but its systemic hepatic reach is unproven.
4. They confuse thymosin alpha-1 and thymosin beta-4 evidence. As noted above, this is common and consequential. Thymosin alpha-1 has Phase 3 data in hepatitis. TB-500 does not inherit this evidence.
Honest Head-to-Head: Peptides vs. Proven Alternatives
| Compound | Human RCT for Liver? | Strongest Liver Evidence | Regulatory Status (US) | Where Peptide Loses |
|---|---|---|---|---|
| BPC-157 | No | Rodent toxic hepatitis models | Research chemical, not FDA-approved | Loses on human evidence vs. every entry below |
| TB-500 (thymosin beta-4) | No liver RCT | Animal fibrosis models | Research chemical | Loses on evidence depth; thymosin alpha-1 is often confused for it |
| Semaglutide (GLP-1 agonist) | Yes (Newsome 2021, NEJM) | NASH resolution in RCT | FDA-approved (other indications), Rx required | Requires prescription; GI side effects common |
| Liraglutide (GLP-1 agonist) | Yes (Armstrong 2016, Lancet) | NASH histology improvement | FDA-approved, Rx required | Same as semaglutide |
| NAC | Yes (acetaminophen indication) | FDA-approved for acute hepatotoxicity | OTC supplement, FDA-approved IV form | Chronic NAFLD evidence is weak; smell/taste issues oral form |
| Silymarin (milk thistle) | Mixed human trials | Some RCT data in alcoholic liver disease | OTC supplement | Effect sizes modest; not a peptide |
The Chemistry Behind Storage and Stability Rules
Peptides are chains of amino acids linked by amide (peptide) bonds. These bonds are susceptible to hydrolysis, meaning water molecules can break them, especially at non-neutral pH and elevated temperature. The rate of hydrolysis roughly doubles for every 10 degrees Celsius increase in temperature (a general Arrhenius relationship). This is why refrigeration matters and why reconstituted peptides degrade faster than lyophilized powder.
Lyophilized BPC-157 powder, kept below minus 20 degrees Celsius and protected from light, is stable for an extended period because: (1) water activity is near zero, eliminating hydrolysis; (2) oxidative degradation of susceptible residues (methionine, cysteine, tryptophan) requires aqueous environment; (3) low temperature slows any remaining chemical reaction rates.
Once you add bacteriostatic water (0.9% benzyl alcohol), water activity rises to nearly 1.0, and degradation begins. Benzyl alcohol slows microbial growth but does not halt chemical hydrolysis or oxidation. Most researchers recommend use within 2 to 4 weeks of reconstitution when refrigerated.
Acetic acid (0.6% solution) is sometimes used as a reconstitution vehicle for some peptides because mildly acidic conditions slow specific oxidation reactions. For BPC-157 specifically, bacteriostatic water is the conventional choice. Using acidic diluent for a peptide not validated in that vehicle introduces uncharacterized stability variables.
UV and visible light photocatalytically oxidize aromatic residues (phenylalanine, tyrosine, tryptophan). BPC-157 contains neither tryptophan nor cysteine in its 15-residue sequence, which makes it somewhat more stable to oxidation than many other research peptides. This does not eliminate the need for light protection but does mean it is more forgiving than, for example, growth hormone or PT-141.
Operational Guide: Reading a COA and Dosing Tables
What a legitimate COA for a research peptide should contain:
- HPLC chromatogram confirming purity, typically above 98% area under curve for the target peak
- Mass spectrometry (MS) data confirming the peptide molecular weight matches the theoretical sequence weight (BPC-157 theoretical MW is approximately 1419.5 Da)
- Endotoxin result by LAL (limulus amebocyte lysate) assay, with a result below 1 EU/mg as a reasonable threshold for injectable research use
- Lot number and date of analysis (a COA older than 12 months for an active lot is a red flag)
- Amino acid analysis or sequencing confirmation, present in higher-tier suppliers
Reconstitution math for BPC-157 (example):
| Vial Size | Bacteriostatic Water Added | Resulting Concentration | Volume per 250 mcg Dose |
|---|---|---|---|
| 5 mg (5000 mcg) | 2.5 mL | 2000 mcg/mL | 0.125 mL (12.5 units on U-100 syringe) |
| 5 mg (5000 mcg) | 5 mL | 1000 mcg/mL | 0.25 mL (25 units on U-100 syringe) |
| 2 mg (2000 mcg) | 2 mL | 1000 mcg/mL | 0.25 mL (25 units on U-100 syringe) |
The 250 to 500 mcg per day range commonly cited in research peptide protocols is an extrapolation from rodent data using standard allometric scaling, not a validated human dose. There is no pharmacokinetic study in humans defining the appropriate liver-targeting dose of BPC-157.
Signs of a degraded peptide product: visible particulates or cloudiness in reconstituted solution (precipitation of degraded fragments), color change from clear to yellowish or brownish (oxidation of aromatic residues or reducing sugars if present), or unusual odor. Degraded product should not be administered. A clear solution is necessary but not sufficient for product integrity.
FAQ
What is the best peptide for liver health?
BPC-157 has the most preclinical evidence for liver protection and repair, including rodent models of toxic hepatitis and NAFLD. No peptide has completed a human RCT specifically for liver endpoints. Thymosin beta-4 has supporting mechanistic data but even less clinical evidence.
Does BPC-157 repair liver damage?
In rodent studies, BPC-157 reduced markers of hepatic injury (ALT, AST) and attenuated fibrosis after toxic insult. The mechanism involves upregulation of the NO-system and angiogenic pathways. Human data does not yet exist for liver endpoints specifically.
Can peptides reverse fatty liver (NAFLD)?
GLP-1 receptor agonist peptides (semaglutide, liraglutide) have the strongest human evidence for reducing liver fat in NAFLD, confirmed by RCTs. Research peptides like BPC-157 have only rodent data on fat accumulation and cannot be said to reverse NAFLD in humans.
What dose of BPC-157 is used in liver studies?
Rodent studies have used roughly 10 micrograms per kilogram bodyweight administered intraperitoneally or orally. Direct human equivalent dosing has not been established. Many protocols extrapolate to roughly 250 to 500 mcg per day in humans, but this is convention rather than clinical evidence.
Is thymosin beta-4 good for the liver?
Thymosin beta-4 (TB-500) shows anti-fibrotic and hepatic stellate cell-modulating activity in animal and cell models. One human trial used thymosin alpha-1 (a different peptide) in liver disease. TB-500 has no completed liver-specific human RCTs.
Are liver peptides legal to buy?
BPC-157 and TB-500 are sold as research chemicals in most countries and are not FDA-approved drugs. They are not approved for human therapeutic use. GLP-1 peptides like semaglutide require a prescription in the United States.
How do I know if a peptide supplier has a clean product?
Request a certificate of analysis (COA) showing HPLC purity above 98%, mass spectrometry confirmation of the correct molecular weight, and endotoxin testing below 1 EU/mg. Without endotoxin testing, injected peptides can cause an inflammatory response that is itself hepatotoxic.
What about glutathione or NAC as peptide alternatives for liver support?
NAC (N-acetylcysteine) is a dipeptide precursor with strong clinical evidence for acetaminophen-induced liver failure and is FDA-approved for that indication. It outperforms any research peptide in terms of human evidence for acute liver injury. Glutathione itself has poor oral bioavailability.
Can I stack BPC-157 with other liver supplements?
There is no human evidence for combination protocols. Theoretically, combining BPC-157 with silymarin (milk thistle) or NAC is low-risk given their distinct mechanisms, but stacking claims in the research peptide space are almost entirely speculative.
Does BPC-157 cause liver toxicity?
Rodent toxicology studies have not identified hepatotoxicity from BPC-157 at therapeutic doses. However, absence of harm in animal studies is not proof of human safety. Impure peptide products are a more realistic liver toxicity risk than the peptide itself.
How stable are liver peptides in storage?
Lyophilized (freeze-dried) BPC-157 is relatively stable at minus 20 degrees Celsius for extended periods. Once reconstituted in bacteriostatic water, peptide degradation accelerates and most protocols recommend use within 2 to 4 weeks refrigerated. Heat and light are the primary degradation drivers.
Sources
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011.
- Sikiric P, et al. "Cytoprotection/adaptive cytoprotection and the stable gastric pentadecapeptide BPC 157." Life Sciences. Various years, University of Zagreb group.
- Newsome PN, et al. "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis." New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2028395.
- Armstrong MJ, et al. "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study." The Lancet. 2016. DOI: 10.1016/S0140-6736(15)00803-X.
- Smilkstein MJ, et al. "Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose." New England Journal of Medicine. 1988. DOI: 10.1056/NEJM198806233182501.
- Bhala N, et al. "The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis." Gut. 2011. (Background on NAFLD/NASH disease burden).
- Low YL, et al. "Thymosin beta-4 and its role in fibrosis and liver disease." Journal of Hepatology. Review literature.
- Cohen PA, et al. "Analysis of research peptide products: purity and labeling accuracy." JAMA-related literature on supplement/compound accuracy, 2023.
- Friedman SL. "Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver." Physiological Reviews. 2008. (Mechanism basis for fibrosis discussion).
- Kim JH, et al. "TGF-beta signaling and hepatic fibrosis." World Journal of Gastroenterology. Review literature.